Invention Application
- Patent Title: BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES
-
Application No.: US14058164Application Date: 2013-10-18
-
Publication No.: US20140057890A1Publication Date: 2014-02-27
- Inventor: Milan Bruncko , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa Hasvold , Laura A. Hexamer , Aaron R. Kunzer , Robert A. Mantei , William J. McClellan , Chang H. Park , Cheol-Min Park , Andrew M. Petros , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt
- Applicant: AbbVie Inc.
- Applicant Address: US IL North Chicago
- Assignee: AbbVie Inc.
- Current Assignee: AbbVie Inc.
- Current Assignee Address: US IL North Chicago
- Main IPC: A61K31/5377
- IPC: A61K31/5377 ; A61K31/496 ; C07D413/06 ; C07D401/06 ; A61K45/06 ; A61K31/407 ; C07D403/06 ; A61K31/501 ; C07D241/04 ; A61K31/495 ; C07D405/06 ; C07D487/04
Abstract:
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
Public/Granted literature
- US09072748B2 BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases Public/Granted day:2015-07-07
Information query
IPC分类:
